Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1141 to 1155 of 1310 results for long term conditions

  1. Evidence on the safety and efficacy of intramedullary distraction for upper limb lengthening is inadequate in quantity and quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long as special arrangements for clinical governance, consent, and audit or research are in place. Find out what special arrangements mean on the NICE interventional procedures guidance page. Further research, which could be registry data, should report details of patient  selection, device selection, technique used, procedural outcomes, long-term  outcomes including quality of life, the need for repeat interventions or surgery and complication rates.

    quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long...

    Research recommendation
    Published
    11 May 2022

  2. Transition in special groups: looked-after young people:- What is the most effective way of supporting care leavers in transition from children's to adults' health services?

    birth parents in the management of childhood-onset long-term physical and mental health conditions is...

    Research recommendation
    Published
    21 March 2016

  3. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  4. Tools for case identification for cognitive impairment in criminal justice system populations:- What are the reliable and valid tools to identify cognitive impairment among people in contact with the criminal justice system (including people who have experienced physical trauma, neurodevelopmental disorders or other acquired cognitive impairment)?

    of, for example, traumatic brain injury, a stroke or other neurological conditions. Experts in this area have suggested that...

    Research recommendation
    Published
    16 May 2017

  5. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

    Medtech innovation briefing
    Published
    10 June 2016

  6. Compression products for treating venous leg ulcers: late-stage assessment (HTG758)

    Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.

    HealthTech guidance
    Published
    27 August 2025
    View recommendations

    Sections for HTG758

  7. DOAC Dipstick for detecting direct oral anticoagulants (MIB248)

    NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .

    Medtech innovation briefing
    Published
    2 February 2021

  8. Mega Soft Patient Return Electrode for use during monopolar electrosurgery (HTG290)

    Evidence-based recommendations on Mega Soft Patient Return Electrode for use during monopolar electrosurgery.

    HealthTech guidance
    Published
    22 August 2012
    View recommendations

    Sections for HTG290

  9. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

    Highly specialised technologies guidance
    Published
    22 February 2017
    View recommendations

    Sections for HST4

  10. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA340

  11. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

    NICE guideline
    Last updated
    27 May 2025
    View recommendations

    Sections for NG140

  12. Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

    Evidence-based recommendations on bevacizumab (Avastin), with paclitaxel and carboplatin, for treating advanced ovarian cancer in adults.

    Technology appraisal guidance
    Published
    22 May 2013
    View recommendations

    Sections for TA284

  13. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

    Antimicrobial prescribing guideline
    Published
    23 July 2021
    View recommendations

    Sections for NG199

  14. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

    Medtech innovation briefing
    Published
    10 August 2021

  15. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329